Preclinical experimental therapeutic approaches in soft tissue sarcoma

Seminars in Surgical Oncology

Volumn 17, Issue 1, 1999, Pages 78-82

  Hunt, Kelly K ^a   Feig, Barry W ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenovirus E2F; Antisense DNA; Apoptosis; Cell cycle; DNA binding proteins; Fusion oncogene proteins; Gene expression regulation; Mutation; Myc genes; NF kappa B; P53 gene; Proto oncogene proteins; Ras genes; Retinoblastoma genes; Sarcoma; Soft tissue neoplasms; Transcription factors; Translocation (genetics); Tumor necrosis factor; Tumor suppressor genes

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER INHIBITION; CYTOGENETICS; DRUG MECHANISM; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; GENE THERAPY; METASTASIS; ONCOGENE; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HUMANS; ONCOGENES; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0033012610     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199907/08)17:1<78::AID-SSU10>3.0.CO;2-X     Document Type: Review

References (27)

1. Sorensen PH, Triche TJ: Gene fusions encoding chimaeric transcription factors in solid tumours [Review]. Semin Cancer Biol 1996;7:3-14.
2. rd, et al: The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc Natl Acad Sci USA 1996;93:9805-9809.
3. Tanaka K, Iwakuma T, Harimaya K, et al: EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-247.
4. Latres E, Drobnjak M, Pollack D, et al: Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am J Pathol 1994;145:345-355.
5. Pollock RE, Lang A, Luo J, et al: Soft tissue sarcoma metastasis form clonal expansion of p53 mutated tumor cells. Oncogene 1996;12:2035-2039.
6. Pollock R, Lang A, Ge T, et al: Wild-type p53 and a p53 temperature-sensitive mutant suppress human soft tissue sarcoma by enhancing cell cycle control. Clin Cancer Res 1998;4:1985-1994.
7. nd Annual Cancer Symposium. Society of Surgical Oncology; 1999 March 4-7; Orlando, FL. Arlington Heights, IL;1999. 1999:23: #57.
8. th Annual Meeting of the American Association of Cancer Research; 1999 Apr 10-14; Philadelphia, PA; Philadelphia: AACR;1999. 1999;40: 415 #2742.
9. Nguyen DM, Spitz FR, Yen N, et al: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic ciplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996;112:1372-1377.
10. Spitz FR, Nguyen D, Skibber JM, et al: Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 1996;2:1665-1671.
11. Wang CY, Mayo MW, Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science 1996;274(5288):784-787.
12. Beg AA, Sha WC, Bronson RT, et al: Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995;376(6536):167-170.
13. Grilli M, Chiu JJ, Lenardo MJ: NF-kappa B and Rel: participants in a multiform transcriptional regulatory system [Review]. Int Rev Cytol 1993;143:1-62.
14. Nolan GP, Baltimore D: The inhibitory ankyrin and activator Rel proteins [Review]. Curr Opin Gene Dev 1992;2:211-220.
15. Beg AA, Baldwin AS Jr: The I kappa B proteins: multifunctional regulators of Rel/ NF-kappa B transcription factors [Review]. Genes Dev 1993;7:2064-2070.
16. Brockman JA, Scherer DC, McKinsey TA, et al: Coupling of a signal response domain in I kappa B to multiple pathways for NF-kappa B activation. Mol Cell Biol 1995;15:2809-2818.
17. Traencker EB, Pahl HL, Henkel T, et al: Phosphorylation of human I kappa B on serines 32 and 36 controls I kappa B proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J 1995;14:2876-2883.
18. Brown K, Gerstberger FS, Carlson L, et al: Control of I kappa B-alpha protealysis by site-specific, signal-induced phosphorylation. Science 1995;267(5203):1485-1488.
19. Chen Z, Hagler J, Palombella VJ, et al: Signal-induced site-specific phosphorylation targets I kappa B-alpha to the ubiquitin-proteasome pathway. Genes Dev 1995;9:1586-1597.
20. Feig BW, Lu X, Hunt KK, et al: Inhibition of the transcription factor NF-kappa B by adenoviral-mediated expression of I kappa B-alpha M results in tumor in cell death. Surgery. In press.
21. Zhang WW, Alemany R, Wang J, et al: Safety evaluation of Ad5CMV-p53 in vitro and in vivo. Human Gene Ther 1995;6: 155-164.
22. Eggermont AM, Schraffordt Koops H, Klausner JM, et al: Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-765.
23. Milas M, Feig B, Yu D, et al: Isolated limb perfusion in the sarcoma-bearing rat: a novel preclinical gene delivery system. Clin Cancer Res 1997;3(12 Pt 1):2197-2203.
24. Hunt KK, Deng J, Liu TJ, et al: Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 1997;57:4722-4726.
25. Hunt KK, Liu TJ, Feig B, et al: Induction of apoptosis in a leiomyosarcoma cell line by adenoviral-mediated over-expression of the transcription factor E2F-1 [Abstract]. Sarcoma J 1997; 1:194-195.
26. th Annual Meeting of the American Association for Cancer Research; 1998 March 28-April 1; New Orleans, LA. Philadelphia: AACR;1998. 1998; 39:137 #936.
27. Hetrakul N, Abramian A, Liu TJ, et al: Growth inhibition of leiomyosarcoma in vivo using an adenovirus overexpressing the transcription factor E2F-1 [Abstract]. Sarcoma J 1999;3:49 #1.